Madrigal Pharmaceuticals, INC. (MDGL) — SEC Filings

Overview

Madrigal Pharmaceuticals, INC. (MDGL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 11, 2025: Madrigal Pharmaceuticals, Inc. announced on December 5, 2025, changes related to its board of directors and executive compensation. Specifically, the company reported the departure of a director and adjustments to compensatory arrangements for certain officers. The filing also includes information o

Sentiment Summary

Across 38 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 35 neutral, 1 mixed. The dominant filing sentiment for Madrigal Pharmaceuticals, INC. is neutral.

Filing Type Overview

Madrigal Pharmaceuticals, INC. (MDGL) has filed 17 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 9 SC 13G/A, 1 SC 13G, 1 SC 13D/A with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (38)

• Madrigal Pharmaceuticals Announces Director, Officer, and Compensation Changes — 8-K · Dec 11, 2025 Risk: low
  Madrigal Pharmaceuticals, Inc. announced on December 5, 2025, changes related to its board of directors and executive compensation. Specifically, the company re
• Madrigal's Rezdiffra Fuels Revenue Surge Amidst Rising Costs — 10-Q · Nov 4, 2025 Risk: medium
  Madrigal Pharmaceuticals, Inc. (MDGL) reported a significant increase in product revenue, reaching $287.268 million for the three months ended September 30, 202
• Madrigal's Q2 Loss Widens to $150M Amid R&D Push — 10-Q · Aug 5, 2025 Risk: high
  Madrigal Pharmaceuticals, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods, as the company rema
• Madrigal Pharmaceuticals Files 8-K — 8-K · Jul 30, 2025 Risk: low
  Madrigal Pharmaceuticals, Inc. filed an 8-K on July 30, 2025, reporting under Regulation FD and including financial statements and exhibits. The filing details
• Madrigal Pharmaceuticals Terminates Agreement, Enters New One — 8-K · Jul 22, 2025 Risk: medium
  Madrigal Pharmaceuticals, Inc. announced on July 17, 2025, the termination of a material definitive agreement. The company also entered into a new material defi
• Madrigal Pharmaceuticals Files 8-K for Security Holder Vote — 8-K · Jun 20, 2025 Risk: medium
  Madrigal Pharmaceuticals, Inc. filed an 8-K on June 20, 2025, to report the submission of matters to a vote of its security holders. The filing does not disclos
• Madrigal Pharmaceuticals Files Q1 2025 10-Q Report — 10-Q · May 1, 2025 Risk: medium
  Madrigal Pharmaceuticals, Inc. filed its quarterly report for the period ending March 31, 2025. The company, headquartered in West Conshohocken, PA, reported it
• Madrigal Pharma Files Definitive Proxy Statement — DEF 14A · Apr 29, 2025 Risk: low
  Madrigal Pharmaceuticals, Inc. filed its definitive proxy statement on April 29, 2025, for its annual meeting of stockholders scheduled for June 20, 2025. The f
• Madrigal Pharma Appoints New Chief Medical Officer — 8-K · Apr 17, 2025 Risk: medium
  Madrigal Pharmaceuticals, Inc. announced on April 16, 2025, the appointment of Dr. Marc Walter as Chief Medical Officer. Dr. Walter previously served as Senior
• Madrigal Pharma Appoints New Chief Medical Officer — 8-K · Mar 11, 2025 Risk: low
  Madrigal Pharmaceuticals, Inc. announced on March 9, 2025, the appointment of Dr. Aleksej Z. Mrvaljevic as Chief Medical Officer, effective March 11, 2025. Dr.
• Madrigal Pharmaceuticals Files 8-K on Financials — 8-K · Feb 26, 2025 Risk: low
  Madrigal Pharmaceuticals, Inc. filed an 8-K on February 26, 2025, reporting on its results of operations and financial condition. The filing also includes finan
• Madrigal Pharmaceuticals Files 2024 10-K — 10-K · Feb 26, 2025 Risk: medium
  Madrigal Pharmaceuticals, Inc. filed its 2024 10-K on February 26, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The c
• Madrigal Pharmaceuticals Files 8-K — 8-K · Jan 13, 2025 Risk: low
  Madrigal Pharmaceuticals, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition, and including financial stateme
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G Filing — SC 13G · Nov 14, 2024
• Madrigal Pharmaceuticals Files 8-K on Financials — 8-K · Oct 31, 2024 Risk: low
  Madrigal Pharmaceuticals, Inc. filed an 8-K on October 31, 2024, reporting results of operations and financial condition. The filing also includes financial sta
• Madrigal Pharmaceuticals Files Q3 2024 10-Q Report — 10-Q · Oct 31, 2024 Risk: low
  Madrigal Pharmaceuticals, Inc. filed its quarterly report for the period ending September 30, 2024. The company is incorporated in Delaware and headquartered in
• Madrigal Pharmaceuticals Files 8-K on Financials — 8-K · Aug 7, 2024 Risk: low
  Madrigal Pharmaceuticals, Inc. filed an 8-K on August 7, 2024, reporting on its results of operations and financial condition. The filing details financial stat
• Madrigal Pharmaceuticals Files Q2 2024 10-Q — 10-Q · Aug 7, 2024 Risk: medium
  Madrigal Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results for the second quarter and the first h
• Madrigal Pharmaceuticals Appoints New CMO, Elects Directors — 8-K · Jun 27, 2024 Risk: low
  Madrigal Pharmaceuticals, Inc. announced on June 25, 2024, the appointment of Dr. Elias J. Growe as Chief Medical Officer, effective immediately. Dr. Growe prev
• Madrigal Pharmaceuticals Files 8-K — 8-K · May 7, 2024 Risk: low
  Madrigal Pharmaceuticals, Inc. filed an 8-K on May 7, 2024, reporting on its results of operations and financial condition, and including financial statements a
• Madrigal Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 7, 2024 Risk: low
  MADRIGAL PHARMACEUTICALS, INC. (MDGL) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Madrigal Pharmaceuticals, Inc. filed a 10-Q report for the pe
• Madrigal Pharmaceuticals Files Definitive Proxy Statement — DEF 14A · Apr 29, 2024 Risk: low
  MADRIGAL PHARMACEUTICALS, INC. (MDGL) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Madrigal Pharmaceuticals, Inc. filed a Definitive Proxy
• Madrigal Pharma Secures $500M Credit Facility — 8-K · Apr 2, 2024 Risk: low
  Madrigal Pharmaceuticals, Inc. announced on March 27, 2024, that it has entered into a new credit agreement with JPMorgan Chase Bank, N.A. This agreement provid
• Baker Bros. Advisors Updates Madrigal Pharma Stake — SC 13D/A · Mar 25, 2024 Risk: medium
  Baker Bros. Advisors LP, through its affiliates, has amended its Schedule 13D filing regarding Madrigal Pharmaceuticals, Inc. as of March 25, 2024. The filing i
• Madrigal Pharmaceuticals Enters Material Definitive Agreement — 8-K · Mar 20, 2024 Risk: medium
  Madrigal Pharmaceuticals, Inc. announced on March 18, 2024, that it entered into a Material Definitive Agreement. The filing does not disclose specific details
• Madrigal Pharma Buys Gene Therapy Assets from Arrowhead — 8-K · Mar 15, 2024 Risk: medium
  Madrigal Pharmaceuticals, Inc. announced on March 14, 2024, that it has entered into a definitive agreement to acquire a portfolio of gene therapy programs from
• Madrigal Pharma Files 8-K on Financial Condition — 8-K · Feb 28, 2024 Risk: low
  Madrigal Pharmaceuticals, Inc. filed an 8-K on February 28, 2024, reporting on its results of operations and financial condition. The filing, under SEC File Num
• Madrigal Pharmaceuticals, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 28, 2024 Risk: low
  MADRIGAL PHARMACEUTICALS, INC. (MDGL) filed a Annual Report (10-K) with the SEC on February 28, 2024. Madrigal Pharmaceuticals, Inc. reported its 2023 fiscal ye
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• BlackRock Amends Madrigal Pharma Stake, Maintains Institutional Holding — SC 13G/A · Jan 29, 2024
  BlackRock Inc. filed an amended SC 13G/A on January 29, 2024, disclosing its ownership in Madrigal Pharmaceuticals, Inc. as of December 31, 2023. This filing in
• State Street Corp. Updates Passive Stake in Madrigal Pharma — SC 13G/A · Jan 22, 2024
  State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 22, 2024, indicating its ownership of Madrigal Pharmaceuticals, In
• Madrigal Pharma Updates Business Address in 8-K Filing — 8-K · Jan 8, 2024
  Madrigal Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, to update its business address to Four Tower Bridge, 200 Barr Harbor Drive, Suite 200, West Cons

Related Companies

ARWR

Frequently Asked Questions